Herpes Simplex Virus News and Research

RSS

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

The University of Illinois at Chicago's Center for Clinical and Translational Science has selected six research projects to receive pilot grants in 2013.

15 May 2013

Scientists identify new class of immune cells that suppress genital herpes

Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes.

9 May 2013

Adult male circumcision reduces bacteria living on penis, study shows

Circumcision drastically alters the microbiome of the penis, changes that could explain why circumcision offers protection against HIV and other viral infections.

17 Apr 2013

Study: Circumcision does not increase risk of herpes in infants

Jewish leaders this week pointed to a recent independent study by Penn Medicine at the University of Pennsylvania that found little evidence to support the claim that a circumcision practice known as Metzitzah B'Peh (MBP) leads to an increased likelihood of herpes in infants.

10 Apr 2013

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.

4 Apr 2013

A new strategy to prevent herpes virus infections

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing infections due to the highly common herpes simplex viruses, the microbes responsible for causing genital herpes (herpes simplex virus 2) and cold sores (herpes simplex virus 1).

26 Mar 2013

New therapeutic approach for bladder pain syndrome

Severe chronic pain associated with conditions such as bladder pain syndrome/interstitial cystitis often require the use of opioid medication, with the risk of dependency and serious adverse reactions.

15 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Cancer-killing viruses found safe but less effective than expected

Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.

26 Nov 2012

Viruses to treat metastatic cancers

There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?

15 Nov 2012

Alpha-herpesvirus axon-to-cell spread involves limited virion transmission

New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.

7 Nov 2012

Virttu launches REPLICATE- Open Innovation Forum

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.

6 Nov 2012

Genocea raises $30M in Series C financing round

Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round.

10 Oct 2012

FDA clears Roche's automated type-specific herpes tests

Roche announced today that it has received clearance from the U.S. Food and Drug Administration for its IgG Antibody to herpes simplex virus types 1 and 2 assays for use on cobas modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.

From Roche Sequencing and Life Science 5 Sep 2012

Declining circumcision rates in the US raise healthcare costs and disease risk

A team of disease experts and health economists at Johns Hopkins warns that steadily declining rates of U.S. infant male circumcision could add more than $4.4 billion in avoidable health care costs if rates over the next decade drop to levels now seen in Europe.

21 Aug 2012

Declining rates of circumcision in US infant males could add billions to health care costs

21 Aug 2012

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.

16 Aug 2012

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2).

6 Aug 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012